Trading Report: Today, 3,000 Shares of Spark Therapeutics Inc. (ONCE) Stock are sold by Barge Joseph La

Today, 3,000 Shares of Spark Therapeutics Inc. (ONCE) Stock are sold by Barge Joseph La

Spark Therapeutics Inc. (NASDAQ:ONCE) insider Barge Joseph La sold 3,000 shares of the business’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $60.14, for a total value of $180,420.00. Following the transaction, the insider now directly owns 8,325 shares of the company’s stock, valued at approximately $500,665.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Spark Therapeutics Inc. (NASDAQ:ONCE) opened at 60.49 on Friday. Spark Therapeutics Inc. has a one year low of $21.20 and a one year high of $65.99. The company has a 50-day moving average price of $59.35 and a 200 day moving average price of $49.53. The company’s market capitalization is $1.85 billion.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by $0.07. The company had revenue of $1.29 million for the quarter, compared to analysts’ expectations of $1.17 million. Spark Therapeutics had a negative net margin of 366.76% and a negative return on equity of 26.96%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.60) earnings per share. Equities analysts anticipate that Spark Therapeutics Inc. will post ($3.96) EPS for the current year.

Several brokerages have commented on ONCE. Jefferies Group reissued a “hold” rating on shares of Spark Therapeutics in a research note on Sunday, June 12th. Chardan Capital set a $35.00 target price on Spark Therapeutics and gave the stock a “hold” rating in a research note on Thursday, July 21st. Cantor Fitzgerald reissued a “buy” rating on shares of Spark Therapeutics in a research note on Thursday, July 14th. Wedbush reissued an “underperform” rating and set a $29.00 target price (up previously from $28.00) on shares of Spark Therapeutics in a research note on Wednesday, August 10th. Finally, Zacks Investment Research raised Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research note on Thursday, August 11th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $59.50.

Hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in shares of Spark Therapeutics by 14.6% in the first quarter. JPMorgan Chase & Co. now owns 679,220 shares of the company’s stock worth $20,045,000 after buying an additional 86,659 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in shares of Spark Therapeutics by 7.3% in the first quarter. UBS Asset Management Americas Inc. now owns 152,972 shares of the company’s stock worth $4,514,000 after buying an additional 10,472 shares during the last quarter. AXA increased its position in shares of Spark Therapeutics by 52.7% in the first quarter. AXA now owns 247,788 shares of the company’s stock worth $7,312,000 after buying an additional 85,478 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Spark Therapeutics by 9.0% in the first quarter. Geode Capital Management LLC now owns 100,565 shares of the company’s stock worth $2,967,000 after buying an additional 8,289 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Spark Therapeutics by 3.6% in the first quarter. Wellington Management Group LLP now owns 436,232 shares of the company’s stock worth $12,872,000 after buying an additional 15,232 shares during the last quarter. 78.79% of the stock is currently owned by institutional investors and hedge funds.

About Spark Therapeutics

Related posts

Leave a Comment